These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 30510255)

  • 1. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level.
    Chen J; Kao YR; Sun D; Todorova TI; Reynolds D; Narayanagari SR; Montagna C; Will B; Verma A; Steidl U
    Nat Med; 2019 Jan; 25(1):103-110. PubMed ID: 30510255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
    Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
    Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Jain AG; Ball S; Aguirre L; Al Ali N; Kaldas D; Tinsley-Vance S; Kuykendall A; Chan O; Sweet K; Lancet JE; Padron E; Sallman DA; Komrokji R
    Haematologica; 2024 Jul; 109(7):2157-2164. PubMed ID: 38299605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Research progress on mechanism of MDS transformation into AML].
    Wang LL; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.
    Stosch JM; Heumüller A; Niemöller C; Bleul S; Rothenberg-Thurley M; Riba J; Renz N; Szarc Vel Szic K; Pfeifer D; Follo M; Pahl HL; Zimmermann S; Duyster J; Wehrle J; Lübbert M; Metzeler KH; Claus R; Becker H
    Br J Haematol; 2018 Sep; 182(6):830-842. PubMed ID: 29974943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
    Jiang Y; Dunbar A; Gondek LP; Mohan S; Rataul M; O'Keefe C; Sekeres M; Saunthararajah Y; Maciejewski JP
    Blood; 2009 Feb; 113(6):1315-25. PubMed ID: 18832655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics of progression from MDS to secondary leukemia.
    Menssen AJ; Walter MJ
    Blood; 2020 Jul; 136(1):50-60. PubMed ID: 32430504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
    Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
    Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
    Bernasconi P
    Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.
    Liao R; Xu Y; Chen M; Chen X; Zhan X; Sun J
    Hematology; 2013 Jul; 18(4):191-7. PubMed ID: 23321417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia.
    Woll PS; Yoshizato T; Hellström-Lindberg E; Fioretos T; Ebert BL; Jacobsen SEW
    J Intern Med; 2022 Aug; 292(2):262-277. PubMed ID: 35822488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What biologic factors predict for transformation to AML?
    Bejar R
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):341-345. PubMed ID: 30466744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Nucleotide Variations, Insertions/Deletions and Copy Number Variations in Myelodysplastic Syndrome during Disease Progression Revealed by a Single-Cell DNA Sequencing Platform.
    Lee P; Yim R; Fung SH; Miu KK; Wang Z; Wu KC; Au L; Leung GM; Lee VH; Gill H
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes.
    Kwon A; Weinberg OK
    Clin Lab Med; 2023 Dec; 43(4):657-667. PubMed ID: 37865509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.
    Neukirchen J; Lauseker M; Hildebrandt B; Nolting AC; Kaivers J; Kobbe G; Gattermann N; Haas R; Germing U
    Cancer; 2017 Dec; 123(23):4608-4616. PubMed ID: 28746789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression.
    Menssen AJ; Khanna A; Miller CA; Nonavinkere Srivatsan S; Chang GS; Shao J; Robinson J; O'Laughlin M; Fronick CC; Fulton RS; Brendel K; Heath SE; Saba R; Welch JS; Spencer DH; Payton JE; Westervelt P; DiPersio JF; Link DC; Schuelke MJ; Jacoby MA; Duncavage EJ; Ley TJ; Walter MJ
    Blood Cancer Discov; 2022 Jul; 3(4):330-345. PubMed ID: 35709710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
    Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
    Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
    Badar T; Patel KP; Thompson PA; DiNardo C; Takahashi K; Cabrero M; Borthakur G; Cortes J; Konopleva M; Kadia T; Bohannan Z; Pierce S; Jabbour EJ; Ravandi F; Daver N; Luthra R; Kantarjian H; Garcia-Manero G
    Leuk Res; 2015 Dec; 39(12):1367-74. PubMed ID: 26547258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.